[Therapy of dementing diseases: value of calcium antagonists].
The possibilities and limitations of treatment of dementia with nootropic agents are discussed. Particular attention is directed to the calcium antagonist, nimodipine, with its demonstrably excellent efficacy. Treatment with nootropic agents should be initiated after meticulous establishment of the diagnosis of dementia and continued over the long-term, if their effectiveness is clinically manifest.
Möller
H J
HJ
Psychiatrische Klinik und Poliklinik, Universität Bonn.
D000368:Aged; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D002121:Calcium Channel Blockers / Q000008:administration & dosage*; D015220:Calcium Channels / Q000187:drug effects / Q000502:physiology; D002986:Clinical Trials as Topic; D003704:Dementia / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D009483:Neuropsychological Tests; D009553:Nimodipine / Q000008:administration & dosage; D011619:Psychotropic Drugs / Q000008:administration & dosage*
D002121:Calcium Channel Blockers; D015220:Calcium Channels; D011619:Psychotropic Drugs; D009553:Nimodipine
Therapie dementieller Erkrankungen: Bedeutung von Kalziumantagonisten.